LY 4175408
Alternative Names: LY-4175408Latest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Oct 2024 Preclinical trials in Solid tumours in USA (Parenteral)
- 23 Oct 2024 Eli Lilly and Company plans to file an IND application for Solid tumours in 2025 (Parenteral)
- 23 Oct 2024 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)